Development
Alnylam Pharmaceuticals, Inc.
ALNY
$300.83
-$7.17-2.33%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 31.25% | 183.96% | 41.78% | 49.72% | 29.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.25% | 183.96% | 41.78% | 49.72% | 29.59% |
| Cost of Revenue | 67.48% | 105.05% | 109.20% | 54.01% | 36.11% |
| Gross Profit | 24.70% | 198.50% | 26.83% | 48.86% | 28.48% |
| SG&A Expenses | -5.81% | -15.55% | 26.30% | 18.90% | 12.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.20% | 2.74% | 31.71% | 30.31% | 15.57% |
| Operating Income | 38.28% | 182.88% | -19.90% | -2.10% | 3.06% |
| Income Before Tax | 33.49% | 137.13% | 0.17% | 27.99% | 20.47% |
| Income Tax Expenses | -61.23% | 13,091.30% | -33.49% | 76.55% | 125.62% |
| Earnings from Continuing Operations | 33.55% | 136.40% | 0.50% | 27.56% | 19.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.55% | 136.40% | 0.50% | 27.56% | 19.72% |
| EBIT | 38.28% | 182.88% | -19.90% | -2.10% | 3.06% |
| EBITDA | 40.95% | 191.82% | -19.31% | 1.11% | 4.85% |
| EPS Basic | 34.79% | 135.51% | 3.50% | 29.73% | 21.99% |
| Normalized Basic EPS | 36.45% | 150.86% | 2.30% | 20.74% | 18.44% |
| EPS Diluted | 35.10% | 134.66% | 3.50% | 29.86% | 21.62% |
| Normalized Diluted EPS | 36.45% | 148.49% | 2.30% | 20.74% | 18.44% |
| Average Basic Shares Outstanding | 1.90% | 2.50% | 3.11% | 3.09% | 2.92% |
| Average Diluted Shares Outstanding | 1.90% | 7.51% | 3.11% | 3.09% | 2.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |